SNTS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
|Jim Simons 2,684,843 sh (+5.33%)||Paul Tudor Jones 11,600 sh (-1.69%)|
Steven Cohen 10,940 sh (-68.37%)
|Joel Greenblatt 66,922 sh (New)|
Steven Cohen 79,817 sh (+629.59%)
Paul Tudor Jones 23,000 sh (+98.28%)
|Jim Simons 2,142,938 sh (-20.18%)|
|John Paulson 5,000,000 sh (New)|
Mario Gabelli 392,700 sh (New)
|Paul Tudor Jones Sold Out|
Steven Cohen Sold Out
Jim Simons 2,136,038 sh (-0.32%)
Joel Greenblatt 25,257 sh (-62.26%)
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
|Guru||Date||Trades||Impact to Portfolio||Price Range * (?)||Current Price||Change from Average||Current Shares|
|John Paulson||2014-03-31||Sold Out||0.79%||$31.96 - $31.97||$ 31.96||0%||0|
|Mario Gabelli||2014-03-31||Sold Out||0.07%||$31.96 - $31.97||$ 31.96||0%||0|
|Joel Greenblatt||2014-03-31||Sold Out||0.02%||$31.96 - $31.97||$ 31.96||0%||0|
|John Paulson||2013-12-31||New Buy||0.79%||$21.05 - $32.18||$ 31.96||14%||5000000|
|Mario Gabelli||2013-12-31||New Buy||0.07%||$21.05 - $32.18||$ 31.96||14%||392700|
|Joel Greenblatt||2013-12-31||Reduce -62.26%||0.03%||$21.05 - $32.18||$ 31.96||14%||25257|
|Joel Greenblatt||2013-09-30||New Buy||0.05%||$21.17 - $27.26||$ 31.96||34%||66922|
|Industry:||Biotechnology » Biotechnology|
|Compare:||NVO, AMGN, GILD, BIIB, CELG » details|
|Traded in other countries:||TW4A.Germany,|
|Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.|
|Mario Gabelli Comments on Valassis Communications Apr 30 2014|
|Mario Gabelli Comments on Santarus Inc. Apr 30 2014|
|Mario Gabelli's ABC Fund First Quarter 2014 Letter Apr 30 2014|
|Mario Gabelli’s Top 5 Fourth-Quarter Stock Buys Feb 07 2014|
|comment on SNTS Mar 06 2013|
|comment on SNTS Mar 02 2013|
|Santarus Inc. Reports Operating Results (10-K) Mar 04 2011|
|Santarus Inc. Reports Operating Results (10-Q) Nov 09 2010|
|Santarus Inc. Reports Operating Results (10-Q) Aug 03 2010|
|Santarus Inc. Reports Operating Results (10-Q) May 07 2010|